Innovator Growth Accelerated Plus ETF - October (BATS: QTOC)

Latest news for Innovator Growth Accelerated Plus ETF - October (BATS:QTOC)

The Fund invests at least 80 percent of its net assets in a portfolio of Flexible Exchange Options that reference the Invesco QQQ Trust, Series 1. The Underlying ETF is a unit investment trust that seeks to track the investment results, before fees and expenses, of the NASDAQ-100 Index, which includes 100 of the largest domestic and international non-financial companies listed on the Nasdaq Stock Market based on market capitalization. To the extent the Underlying ETF concentrates i.e., holds 25 percent or more of its total assets in the securities of a particular industry or group of industries, the Fund will concentrate its investments to approximately the same extent. Through its use of FLEX Options on the Underlying ETF, the Fund has significant exposure to information technology companies.

Innovator Growth Accelerated Plus ETF - October

Sports

General

BREA

Brera Holdings Signs Letter Of Intent To Acquire An Italian Serie B Football Club, Financial Details Not Disclosed

In an investor update on Tuesday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients.
Amgen <a target="_blank" href="https://investors.amgen.com/static-files/a7119a35-06de-497e-ba75-146404c54d95" rel="noreferrer noopener">reported</a> that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.
<ul>
<li>32.8% of rocatinlimab-treated subjects achieved an EASI-75 response at week 24 vs. 13.7% placebo.</li>
<li>19.3% of rocatinlimab-treated subjects achieved a vIGA-AD 0/1 response at week 24 vs. 6.6% placebo.</li>
<li>16.4% of rocatinlimab-treated subjects achieved a rIGA 0/1 response at week 24 vs. 4.9% placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u" rel="noreferrer noopener">Amgen&#8217;s Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts</a>.
MINT Phase 3 trial of Uplizna in generalized myasthenia gravis showed a clinically meaningful and statistically significant MG-ADL (Myasthenia Gravis Activities of Daily Living) score, a measure of the severity of myasthenia gravis symptoms.
After two doses of Uplizna, MG-ADL score showed an overall improvement of -4.2, versus -1.9 placebo adjusted.
The trial demonstrated a statistically significant improvement in the Quantitative Myasthenia Gravis (QMG) score, a clinical assessment that measures the severity of myasthenia gravis.
QMG score improvement with Uplizna compared to placebo at week 26 was -4.8 overall improvement compared to -2.5 placebo adjusted.
No new safety signals were identified.
STAT News <a target="_blank" href="https://www.statnews.com/2024/09/24/amgen-success-trials-eczema-rocatinlimab-myasthenia-gravis-uplizna-competition-remains-stiff/" rel="noreferrer noopener">noted</a> that though the trials succeeded, the therapies did not beat existing competitors on the market.
51% of adults <a target="_blank" href="https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/easi-clinical-trial" rel="noreferrer noopener">treated</a> with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)/ Regeneraon Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) achieved EASI-75 vs.&nbsp;15%&nbsp;with placebo at Week 16 in SOLO 1 trial and 44% vs. 12% in SOLO 2 trial.
William Blair noted that rocatinlimab&#8217;s data fell short of expectations, raising concerns about how its clinical profile stacks up in the increasingly competitive atopic dermatitis market, particularly as the broader ROCKET program unfolds.
On the other hand, the Uplizna results for myasthenia gravis exceeded William Blair&#8217;s expectations, indicating a strong market potential for the treatment. Key advantages include its less frequent dosing and potential to reduce steroid use.
The focus will be determining Uplizna&#8217;s position within the myasthenia gravis treatment landscape alongside other options like FcRn, IVIg, complement inhibitors, rituximab, and more. Additionally, the potential for Uplizna&#8217;s CD19-targeting strategy in autoimmune diseases will be closely watched, especially with competitors like Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>).
Price Action: AMGN stock is trading lower by 2.09% to $324.04 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41021471/private-equity-firms-circle-sanofis-consumer-health-business-amid-potential-spinoff" target="_blank" rel="noreferrer noopener">Private Equity Firms Circle Sanofi&#8217;s Consumer Health Business Amid Potential Spinoff</a>.</li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

AMGN

CGEM

REGN

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

United Homes Group, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>), today announced that on October 1, 2024, Michael Nieri, the Company's founder, Chairman, and Chief Executive Officer, will transition to Executive Chairman of the Company. As Executive Chairman, Mr. Nieri will shift his leadership time and energies to focus primarily on the Company's strategic future. Concurrently with the effectiveness of Mr. Nieri's transition to Executive Chairman, Jamie Pirrello, currently a member of the Company's board of directors and a consultant to the Company, was named interim Chief Executive Officer of the Company. The Company's board of directors intends to undertake a search to identify the Company's next permanent CEO and will consider internal and external candidates.
During his tenure with the Company to date, Mr. Nieri has overseen the tremendous growth and transformation of the Company from the founding of Great Southern Homes in 2004 through its transition to becoming a public company in 2023. Mr. Nieri also helmed the Company through its completion of three homebuilder acquisitions since becoming a public company, and the Company's recent designation as 2024's Builder of the Year by Builder Magazine.

Management

United Homes Group Announces Executive Leadership Changes; On October 1, 2024, Michael Nieri, The Company's Founder, Chairman, And CEO, Will Transition To Executive Chairman Of The Company;  Jamie Pirrello, Was Named Interim Chief Executive Officer Of The Company

Sold-Out Spectacle Also Sets Numerous Other Records While Raising the Bar for Live Sports and Entertainment with Tech and Production Innovations
UFC&#xAE;, part of TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), and Sphere Entertainment Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) today announced that UFC 306 at RIYADH SEASON NOCHE UFC held on September 14 at Sphere in Las Vegas set a number of records, including highest-grossing UFC event of all time and highest-grossing single event at Sphere, with a gate of $22 million and a sold out crowd of 16,024.
UFC 306 AT SPHERE LIVE EVENT RECORDS AND HIGHLIGHTS:
<ul>
<li>Highest-grossing UFC event ever ($22 million), besting the landmark UFC 205: ALVAREZ VS MCGREGOR at Madison Square Garden in New York in November 2016 ($17.7 million).</li>
<li>Highest-grossing single event at Sphere.</li>
<li>Highest-grossing sponsorship sales for a UFC event and the first UFC event with a title partner (Riyadh Season).</li>
<li>Highest-grossing merchandise sales and highest per cap for both a UFC and Sphere event.</li>
<li>Highest-grossing UFC event for On Location VIP Experience packages.</li>
<li>89% of UFC 306 ticket buyers originated from markets outside of Nevada, one of the highest ever for out-of-town ticket sales for both a UFC and Sphere event, reaffirming UFC's power as a live event attraction and tourism draw for the cities that host its events.</li>
</ul>

SPHR

UFC 306 At Sphere Sets Record For Highest-Grossing Event In UFC History And Highest-Grossing Single Event At Sphere With A Gate Of $22M And A Sold Out Crowd Of 16,024

DRRX

DURECT Announces Phase 3 Registrational Trial Design For Larsucosterol In Alcohol-Associated Hepatitis; Type B Meeting With FDA Held Under Breakthrough Therapy Designatoin Resulted In Agreement On Aspects Of Phase 3 Design, Says Single Phase 3 Trial Designed To Enroll 200 U.S. Patients With A 90-day Survival Primary Endpoint; Topline Results Expected Within Two Years Of Trial Initiation

Analysts' ratings for Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Valneva, revealing an average target of $25.5, a high estimate of $26.00, and a low estimate of $23.00. A decline of 1.92% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1727265682_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Valneva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valneva. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Valneva compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Valneva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Valneva's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VALN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Valneva analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Valneva Better</h2>
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, &amp; distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; &amp; Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
<h3>Unraveling the Financial Story of Valneva</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Valneva's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -5.41%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Valneva's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -65.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Valneva's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -14.03%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Valneva's ROA excels beyond industry benchmarks, reaching -5.14%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.26, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VALN

In-Depth Examination Of 6 Analyst Recommendations For Valneva

Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) shares are trading marginally higher on Wednesday <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">in the premarket session.</a>
Today, the company has finalized a partnership with WeRide, an autonomous driving technology firm, to integrate WeRide&#8217;s self-driving vehicles into the Uber platform, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41020151/weride-and-uber-partner-to-bring-autonomous-vehicles-to-the-uber-platform-beginning-in-the-united-" rel="noreferrer noopener">starting in the United Arab Emirates</a>.
The partnership is gearing up for an exciting launch in Abu Dhabi later this year, featuring a fleet of WeRide&#8217;s autonomous vehicles ready to roll through the Uber app. WeRide currently operates the largest robotaxi fleet in the UAE, where residents can access its robotaxi services through the TXAI app.
However, this bold venture won&#8217;t be expanding to the U.S. or China.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41020937/us-stocks-may-stall-after-s-p-500-hits-another-record-micron-earnings-meta-connect-on-traders-radar" rel="noreferrer noopener">US Stocks May Stall After S&amp;P 500 Hits Another Record; Micron Earnings, Meta Connect On Traders&#8217; Radar: Why This Strategist Is Optimistic About Q4</a>
Additionally, in July 2023, WeRide received the UAE&#8217;s first and only national license for self-driving vehicles, which permits the testing and operation of its autonomous vehicles on public roads throughout the country.
Earlier this month, Uber inked a multi-year delivery partnership with Darden Restaurants, Inc., <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40935338/darden-and-uber-partner-to-introduce-on-demand-delivery-with-olive-garden-the-first-to-pilot" rel="noreferrer noopener">set to begin with Olive Garden in late 2024.</a>
The agreement will enable restaurant guests to order on-demand delivery via Darden restaurant channels, with delivery handled by Uber Direct, through Uber&#8217;s national delivery network.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, UBER stock has gained over 72% in the past year. Investors can gain exposure to the stock via iShares Trust iShares U.S. Transportation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYT#BATS">IYT</a>) and&nbsp;Franklin Disruptive Commerce ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BUYZ#BATS">BUYZ</a>).
Price Action: UBER shares are trading higher by 0.59% to $77.90 premarket at last check Wednesday.
Photo by Daniel Fung on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41018183/did-aping-warren-buffett-and-hedge-fund-managers-bring-success-to-this-ai-powered-etf-that-launc" target="_blank" rel="noreferrer noopener">Did Aping Warren Buffett And Hedge Fund Managers Bring Success To This AI-Powered ETF That Launched Last Week?</a></li>
</ul>

Equities

Markets

Movers

BUYZ

iShares Dow Jones Transportation Average Index Fund

UBER

Uber Teams With WeRide For UAE Robotaxi Rollout: Details

HP Inc. today announced it has acquired <a href="https://www.globenewswire.com/Tracker?data=vBaJo0IFSWPauTiVr18BgONElNeJxEo4WUCKTsvkA2nv1fhm5nkba-C_CNiA-29fCfdzj6XF6S56WIpNL3SNBA==">Vyopta</a>, an Austin based provider of collaboration management solutions, offering analytics and monitoring for large, unified communications and collaboration (UC) networks. Vyopta brings extensive expertise and infrastructure to turbocharge the development of HP's Workforce Experience <a href="https://www.globenewswire.com/Tracker?data=Ml4veUajLM-NC38x7lJ0YfaYxuS1lWxQIAzM6ObRbm-RrX2ccfWDvGRSA4iy46X8UXwgK4euo9ctJLHqKKuJA2n7BHXgubmTQKbuXq6o9LA=">Platform</a> and provide customers with more insights and capabilities.
The HP Workforce Experience Platform, launched earlier this year, is designed to improve the employee experience and simplify IT management by giving customers control over their digital ecosystem from a single pane of glass. Today's news marks the next step in the Platform journey to create a more comprehensive workplace view for customers and set HP further apart from competitors.

HP Strengthens Workforce Experience Platform With Acquisition Of Vyopta; No Financial Terms Disclosed

Across the recent three months, 10 analysts have shared their insights on Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $29.9, a high estimate of $38.00, and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 5.95% increase from the previous average price target of $28.22.
<img src="https://www.benzinga.com/files/images/story/2024/1727265657_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Foot Locker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Foot Locker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Foot Locker compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Foot Locker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Foot Locker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Foot Locker analyst ratings.</a>
<h2>Delving into Foot Locker's Background</h2>
Foot Locker Inc operates thousands of retail stores throughout the United States, Canada, Europe, Asia, Australia, and New Zealand. It also has a presence in the Middle East. The company mainly sells athletically inspired shoes and apparel. Foot Locker's merchandise comes from only a few suppliers, with Nike providing the majority. Its portfolio of brands, includes Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. The company has omnichannel capabilities to bridge the digital world and physical stores, including order-in-store, buy online and pickup-in-store, and buy online and ship-from-store, as well as e-commerce. It has three operating segments, North America, EMEA, and Asia Pacific.
<h3>Foot Locker's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Foot Locker's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 1.93%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Foot Locker's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Foot Locker's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.41%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Foot Locker's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.17%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Foot Locker's debt-to-equity ratio is below the industry average at 1.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Foot Locker: Insights From 10 Financial Analysts

During the last three months, 18 analysts shared their evaluations of Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $291.94, a high estimate of $340.00, and a low estimate of $250.00. Marking an increase of 9.91%, the current average surpasses the previous average price target of $265.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1727265644_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Monday.Com is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$295.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Alex Zukin</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Monday.Com. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Monday.Com compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Monday.Com's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Monday.Com's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MNDY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Monday.Com analyst ratings.</a>
<h2>Discovering Monday.Com: A Closer Look</h2>
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.
<h3>Financial Milestones: Monday.Com's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Monday.Com's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 34.4%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Monday.Com's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Monday.Com's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.62%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Monday.Com's ROA excels beyond industry benchmarks, reaching 1.0%. This signifies efficient management of assets and strong financial health.
Debt Management: Monday.Com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MNDY

Analyst Ratings For Monday.Com

In the preceding three months, 4 analysts have released ratings for Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Archrock, presenting an average target of $23.75, a high estimate of $25.00, and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 5.56% from the previous average price target of $22.50.
<img src="https://www.benzinga.com/files/images/story/2024/1727265633_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Archrock. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Archrock. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Archrock compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Archrock's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Archrock's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AROC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Archrock analyst ratings.</a>
<h2>Get to Know Archrock Better</h2>
Archrock Inc is an energy infrastructure company with focus on midstream natural gas compression and a commitment to helping customers produce, compress and transport natural gas. It has two business segments, Contract Operations, and Aftermarket Services. Under the umbrella of contract operations services, the company provides operations to meet customers' natural gas compression needs. Services include designing, owning, installing, operating, and maintaining equipment. Aftermarket Services business provides a full range of services to support the compression needs of customers that own compression equipment, including operations, maintenance, overhaul and reconfiguration services and sales of parts and components. It generates maximum revenue from the Contract Operations segment.
<h3>Archrock's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Archrock displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Archrock's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Archrock's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.83%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Archrock's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.27%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Archrock's debt-to-equity ratio surpasses industry norms, standing at 1.81. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AROC

Unveiling 4 Analyst Insights On Archrock

In the latest quarter, 4 analysts provided ratings for Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.5, a high estimate of $70.00, and a low estimate of $56.00. Witnessing a positive shift, the current average has risen by 13.2% from the previous average price target of $54.33.
<img src="https://www.benzinga.com/files/images/story/2024/1727265623_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ultra Clean Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Yang</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ultra Clean Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultra Clean Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ultra Clean Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ultra Clean Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UCTT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultra Clean Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Ultra Clean Hldgs Better</h2>
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are North America, Asia, and Europe.
<h3>Ultra Clean Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Ultra Clean Hldgs showcased positive performance, achieving a revenue growth rate of 22.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Ultra Clean Hldgs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Ultra Clean Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.27%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ultra Clean Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.0%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ultra Clean Hldgs's debt-to-equity ratio surpasses industry norms, standing at 0.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UCTT

Analyst Scoreboard: 4 Ratings For Ultra Clean Hldgs

Smartsheet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) underwent analysis by 18 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.14, with a high estimate of $63.00 and a low estimate of $50.00. This current average reflects an increase of 5.81% from the previous average price target of $54.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1727265612_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Smartsheet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$56.50</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$56.50</td>
<td>$60.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$56.50</td>
<td>$55.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Robert Simmons</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$51.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Smartsheet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Smartsheet compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Smartsheet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Smartsheet's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SMAR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Smartsheet analyst ratings.</a>
<h2>Get to Know Smartsheet Better</h2>
Smartsheet is a provider of collaborative work management software delivered via a cloud-based, software-as-a-service model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases. Smartsheet's offering supports workflow management across teams, provides real-time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per-user basis, and incremental charges for added platform capabilities.
<h3>Understanding the Numbers: Smartsheet's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Smartsheet's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 17.33%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Smartsheet's net margin is impressive, surpassing industry averages. With a net margin of 2.84%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Smartsheet's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.2%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Smartsheet's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.59%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Smartsheet's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMAR

Demystifying Smartsheet: Insights From 18 Analyst Reviews

OCTO: 83% &#x7C; <a href="https://www.benzinga.com//node/41021202">Eightco Holdings Stated That It Has Made Significant Progress In 2024 By Improving Its Balance Sheet, Most Notably Through The Elimination Of $5.4M In Convertible Notes And Increasing Shareholder Equity By $23M</a>
&nbsp;
PRGS: 11% &#x7C; <a href="https://www.benzinga.com//node/41015137">Progress Software Stock Jumps On Q3 Earnings: Revenue Beat, EPS Beat, Raised Guidance And More</a>
&nbsp;
TH: -35% &#x7C; <a href="https://www.benzinga.com//node/41022067">Target Hospitality shares are trading lower after the company announced that the Company's Board of Directors has determined to disband the Special Committee.</a>
&nbsp;
&nbsp;

Trading Ideas

OCTO

PRGS

Market-Moving News for September 25th

WIIM

VTNR

Vertex Energy shares are trading lower after the company announced it filed for Chapter 11 bankruptcy.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</h3>
<ul>
<li>Dividend Yield: 5.24%</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Overweight rating and cut the price target from $60 to $55 on Sept. 13. This analyst has an accuracy rate of 70%.</li>
<li>Fermium Research analyst Frank Mitsch maintained a Hold rating and lowered the price target from $60 to $54 on Sept. 12. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Sept. 12, Dow updated its third-quarter revenue and EBITDA outlook, citing an unplanned event at a Texas ethylene cracker and greater input costs and margin compression in Europe..</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1">latest Dow news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045157/image-199.png" alt="" class="wp-image-564977" style="width:680px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045157/image-199.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045157/image-199-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045157/image-199-768x712.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<h3 class="wp-block-heading">The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>)</h3>
<ul>
<li>Dividend Yield: 5.12%</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained a Neutral rating and lowered the price target from $25 to $18 on Aug. 6. This analyst has an accuracy rate of 70%.</li>
<li>Mizuho analyst John Roberts initiated coverage on the stock with a Neutral rating and a price target of $25 on June 7. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Aug. 1, Chemours reported mixed second-quarter financial results and issued weak third-quarter net sales guidance.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1">trend in CC stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045233/image-200.png" alt="" class="wp-image-564978" style="width:664px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045233/image-200.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045233/image-200-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045233/image-200-768x709.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>)</h3>
<ul>
<li>Dividend Yield: 4.68%</li>
<li>CIBC analyst Hamir Patel maintained a Neutral rating and cut the price target from $10 to $8.5 on Aug. 13. This analyst has an accuracy rate of 60%.</li>
<li>RBC Capital analyst Matthew McKellar maintained a Sector Perform rating and lowered the price target from $10 to $8 on Aug. 12. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Aug. 8, Mercer Intl posted upbeat quarterly sales.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1">breakout in MERC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="877" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045313/image-201.png" alt="" class="wp-image-564979" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045313/image-201.png 877w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045313/image-201-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25045313/image-201-768x723.png 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41013033/top-4-industrials-stocks-which-could-rescue-your-portfolio-this-quarter">Top 4 Industrials Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Dividends

Price Target

Pre-Market Outlook

MERC

Wall Street's Most Accurate Analysts Give Their Take On 3 Materials Stocks With Over 4% Dividend Yields

General Motors shares are trading lower after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and lowered its price target from $47 to $42.

Ford shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight and lowered its price target to $12.

Morgan Stanley analyst Adam Jonas downgrades General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Equal-Weight to Underweight and lowers the price target from $47 to $42.

Downgrades

Morgan Stanley Downgrades General Motors to Underweight, Lowers Price Target to $42

Morgan Stanley analyst Adam Jonas downgrades Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Overweight to Equal-Weight and lowers the price target from $16 to $12.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Innovator Growth Accelerated Plus ETF - October

News

Latest news for Innovator Growth Accelerated Plus ETF - October (BATS:QTOC)